Get the Stockscreener App
427.73
0.44%
-1.87
After Hours:
427.73
Madrigal Pharmaceuticals Inc stock is traded at $427.73, with a volume of 235.51K.
It is down -0.44% in the last 24 hours and down -1.04% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$429.60
Open:
$427.07
24h Volume:
235.51K
Relative Volume:
0.63
Market Cap:
$9.50B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-17.03
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
-3.30%
1M Performance:
-1.04%
6M Performance:
+34.87%
1Y Performance:
+99.73%
1-Day Range:
$420.00
$430.75
1-Week Range:
$416.29
$445.00
52-Week Range:
$200.63
$463.62
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
427.73 | 9.58B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Madrigal Pharmaceuticals Inc. recovery potential after sell offQuarterly Profit Review & Step-by-Step Trade Execution Guides - newser.com
Published on: 2025-10-13 07:32:23 - newser.com
Using RSI to spot recovery in Madrigal Pharmaceuticals Inc.2025 Investor Takeaways & Risk Controlled Stock Pick Alerts - newser.com
Madrigal Pharmaceuticals Grants Equity Awards to New Employees Under 2025 Inducement Plan - MyChesCo
Sivik Global Healthcare LLC Acquires New Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Live market analysis of Madrigal Pharmaceuticals Inc.Portfolio Performance Report & Consistent Return Investment Signals - newser.com
Wealth Enhancement Advisory Services LLC Acquires New Shares in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals (MDGL) Sees Target Price Hike by Oppenheimer | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals stock price target raised by Oppenheimer to $590 - Investing.com Canada
Detecting support and resistance levels for Madrigal Pharmaceuticals Inc.July 2025 Weekly Recap & Accurate Buy Signal Notifications - newser.com
How to monitor Madrigal Pharmaceuticals Inc. with trend dashboardsGold Moves & Fast Entry Momentum Trade Alerts - newser.com
Is Madrigal Pharmaceuticals Inc. stock bottoming outTrade Analysis Summary & Weekly Stock Breakout Alerts - newser.com
Will earnings trigger a reversal in Madrigal Pharmaceuticals Inc.July 2025 Recap & Expert Approved Momentum Trade Ideas - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for Madrigal Pharmaceuticals (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals gains amid takeover speculation - MSN
Madrigal Pharmaceuticals Reports Promising Two-Year Results for MASH Therapy - MSN
What analysts say about Madrigal Pharmaceuticals Inc YDO1 stockSwing Trading Watchlist & Never Miss the Next Wealth Opportunity - earlytimes.in
Madrigal Pharmaceuticals Inc. stock daily chart insightsGold Moves & Accurate Intraday Trade Tips - newser.com
Market reaction to Madrigal Pharmaceuticals Inc.’s recent news2025 Fundamental Recap & Weekly Momentum Stock Picks - newser.com
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Knights of Columbus Asset Advisors LLC Increases Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
How strong is Madrigal Pharmaceuticals Inc. (YDO1) stock earnings growthTrade Analysis Report & Fast Moving Stock Trade Plans - newser.com
Short interest data insights for Madrigal Pharmaceuticals Inc.Quarterly Profit Summary & AI Enhanced Trading Signals - newser.com
Will Madrigal Pharmaceuticals Inc. (YDO1) stock keep high P E multiplesJuly 2025 Rallies & Long-Term Investment Growth Plans - newser.com
Strid Group LLC Buys Shares of 2,500 Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Published on: 2025-10-05 03:01:06 - newser.com
J. Safra Sarasin Holding AG Increases Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals Hits New 52-Week High of $463.48 - Markets Mojo
Signal strength of Madrigal Pharmaceuticals Inc. stock in tech scannersJuly 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
Q3 Earnings Estimate for MDGL Issued By B. Riley - Defense World
How to use Fibonacci retracement on Madrigal Pharmaceuticals Inc.Earnings Overview Report & Technical Pattern Based Signals - newser.com
What is B. Riley's Forecast for MDGL Q3 Earnings? - MarketBeat
Madrigal Pharmaceuticals, Inc. $MDGL Holdings Decreased by AMI Asset Management Corp - MarketBeat
Madrigal Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference - MSN
Madrigal Pharmaceuticals Achieves 114.43% Annual Growth, Marking It as a Multibagger Stock - Markets Mojo
Madrigal Pharmaceuticals Hits Day High with 8.43% Surge in Stock Price - Markets Mojo
Madrigal Pharmaceuticals Hits New 52-Week High of $460.00 - Markets Mojo
What drives Madrigal Pharmaceuticals Inc YDO1 stock priceSupport Zone Identification & Low Risk High Yield - earlytimes.in
Can Prince Pipes and Fittings Limited Reach New Highs in YEAR Resistance Levels ReviewedBreakout Stock Watch & Rapid Profit Growth - earlytimes.in
Madrigal Pharmaceuticals (NASDAQ:MDGL) Reaches New 52-Week High on Analyst Upgrade - Defense World
Madrigal Pharmaceuticals (NASDAQ:MDGL) Hits New 52-Week High After Analyst Upgrade - MarketBeat
Madrigal Pharmaceuticals stock hits all-time high at 457.47 USD By Investing.com - Investing.com Australia
Madrigal Pharmaceuticals stock hits all-time high at 457.47 USD - Investing.com India
Madrigal Pharmaceuticals Advances NASH Treatment with Full Enrollment of MAESTRO-NASH OUTCOMES Trial - MSN
Madrigal Pharmaceuticals: Rezdiffra's US And EU Rollout Remains Promising (NASDAQ:MDGL) - Seeking Alpha
Evaluating Madrigal Pharmaceuticals Inc. with trendline analysisEntry Point & Free Community Consensus Stock Picks - newser.com
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Madrigal Pharmaceuticals Inc Stock (MDGL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sibold William John | President and CEO |
Sep 09 '25 |
Sale |
445.63 |
7,279 |
3,243,741 |
102,474 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):